A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy.
A trial involving patients receiving fluphenazine decanoate was designed to compare the effects of orphenadrine hydrochloride (Disipal) and its major metabolite, tofenacin hydrochloride (Elamol) on the Parkinsonian side-effects and depression occurring during fluphenazine decanoate therapy. The trial was a double-blind one, with crossover. It was found that both drugs exerted an adequate control on the Parkinsonian side-effects, but there was no significant difference between their effects. Ophenadrine, however, was shown to be significantly superior (p less than 0-05) in the control of the depressive side-effects.
D002986:Clinical Trials as Topic; D003863:Depression / Q000139:chemically induced / Q000188:drug therapy*; D005476:Fluphenazine / Q000009:adverse effects*; D006801:Humans; D009966:Orphenadrine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*
D009966:Orphenadrine; C005834:tofenacin; D005476:Fluphenazine